Page last updated: 2024-11-11

omacor

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Omacor: a drug containing the n-3 fatty acids that corrects plasma lipid; antiarrhthymic [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9831414
CHEMBL ID1200711
MeSH IDM0359442

Synonyms (15)

Synonym
omacor
coromega
lovaza
omega-3-acid ethyl ester
icosapent (epa ethyl ester)
CHEMBL1200711
doconexent (dha ethyl ester)
tak-085
k-85
4,7,10,13,16,19-docosahexaenoic acid, ethyl ester, (4z,7z,10z,13z,16z,19z)-, mixt. with (5z,8z,11z,14z,17z)-ethyl 5,8,11,14,17-eicosapentaenoate
zodin
lotriga
861006-80-6
ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate compound with ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate (1:1)
ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate

Research Excerpts

Overview

Omacor is a new omega-3 fatty acid product that is licensed for secondary prevention post-myocardial infarction. Omacor was found to be a safe and effective means of lowering serum triglycerides.

ExcerptReferenceRelevance
"Omacor is a highly potent form of Omega-3 fatty acids that lowers plasma triglycerides."( Omacor and omega-3 fatty acids for treatment of coronary artery disease and the pleiotropic effects.
Kar, S,
)
2.3
"Omacor is a new omega-3 fatty acid product that is licensed for secondary prevention post-myocardial infarction. "( Further reduction in mortality following myocardial infarction.
Abhyankar, B, 2002
)
1.76
"Omacor was found to be a safe and effective means of lowering serum triglycerides over one year in patients with CHD and combined hyperlipidaemia, whose triglycerides remained elevated despite simvastatin treatment."( An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.
Bhatnagar, D; Durrington, PN; France, M; Julier, K; Khan, MA; Mackness, MI; Morgan, J, 2001
)
1.75

Toxicity

ExcerptReferenceRelevance
" Current pharmacologic treatment options are associated with the potential for significant adverse events, which often outweigh the benefits of achieving sinus rhythm."( Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study.
Ellenbogen, KA; Kowey, PR; Naccarelli, GV; Pratt, CM; Reiffel, JA, 2009
)
0.35
"TAK-085 was safe and well tolerated for up to 52 weeks of treatment in Japanese patients with hypertriglyceridemia undergoing lifestyle modification."( Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study.
Kudou, K; Ootake, J; Saito, Y; Tatsuno, I,
)
0.13
" The incidence of adverse events was not significantly different between the 2 groups."( Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.
Ahn, CW; Byun, DW; Han, KA; Han, KH; Hong, SJ; Hong, YJ; Hur, SH; Jeon, HK; Kim, CH; Kim, DB; Kim, HS; Kim, IJ; Kim, S; Kim, SH; Kim, SY; Lee, H; Lee, KJ; Lee, SH; Lim, HS; Lim, SW; Min, K; Park, IB; Sung, J; Won, K; Yu, J, 2018
)
0.68

Bioavailability

ExcerptReferenceRelevance
", Princeton, NJ) was developed to maximize EPA and DHA bioavailability during a low-fat diet."( A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Davidson, MH; Johnson, J; Kling, DF; Kyle, ML; Rooney, MW,
)
0.13
"To compare the relative bioavailability of EPA and DHA from single 4-gram doses of OM-3 FFA and a prescription OM-3 EE (Lovaza(®), GlaxoSmithKline, Research Triangle Park, NC)."( A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Davidson, MH; Johnson, J; Kling, DF; Kyle, ML; Rooney, MW,
)
0.13
"This was a randomized, open-label, single dose, 4-way crossover, bioavailability study of OM-3 FFA and OM-3 EE administered during periods of low-fat and high-fat consumption to 54 overweight adults."( A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Davidson, MH; Johnson, J; Kling, DF; Kyle, ML; Rooney, MW,
)
0.13
"During a low-fat consumption period, the OM-3 FFA formulation provided dramatically improved bioavailability over the OM-3 EE formulation in overweight subjects."( A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Davidson, MH; Johnson, J; Kling, DF; Kyle, ML; Rooney, MW,
)
0.13
", NJ, USA) is a novel ω-3 free fatty acid formulation, developed to maximize eicosapentenoic acid and docosahexenoic acid bioavailability with low-fat diets, suggesting a potential therapeutic advantage compared with ω-3-acid ethyl esters in the treatment of patients with hypertriglyceridemia."( Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.
Kataoka, Y; Nicholls, SJ; Puri, R; Uno, K, 2013
)
0.39
"The systemic bioavailability of free fatty acid (FFA) forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) compared with ethyl ester (EE) forms is dependent on the presence of intestinal lipases and is highest during consumption of high-fat meals."( Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
Curcio, D; Davidson, M; Ferber, S; Johnson, J; Kling, D; Marenco, T; Offman, E, 2013
)
0.39
" OM3CA bioavailability (area under the plasma concentration-time curve from zero to the last measurable concentration) is up to 4-fold greater than that of OM3FA ethyl esters, and unlike ethyl esters, the absorption of OM3CA is not dependent on pancreatic lipase hydrolysis."( The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
Anzalone, D; Backes, J; Catini, J; Hilleman, D, 2016
)
0.43

Dosage Studied

Plasma phospholipid levels of EPA, DHA, and EPA/AA ratios were significantly inversely correlated with increasing body weight and BMI in the Omacor 4-g dosage group. In a post hoc analysis of the first trial results, correlations were found between eicosapentaenoic acid (EPA)/arachidonic acid (AA) and docosahexaenoic Acid (DHA)/AA ratios.

ExcerptRelevanceReference
" Plasma phospholipid levels of EPA, DHA, and EPA/AA ratios were significantly inversely correlated with increasing body weight and BMI in the Omacor 4-g dosage group but not in the Omacor 8-g dosage group."( Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?
Bergstralh, EJ; Bibus, DM; Donadio, JV; Grande, JP, 2006
)
0.54
" During the dosing period EPA increased 460-480% from the baseline concentration, while DHA increased 150-160%."( Simultaneous quantification of total eicosapentaenoic acid, docosahexaenoic acid and arachidonic acid in plasma by high-performance liquid chromatography-tandem mass spectrometry.
Kostner, K; Salm, P; Taylor, PJ, 2011
)
0.37
"8%) subjects dosed with OM-3 FFA maintained an AUC(0-t) that was ≥50% of the respective high-fat AUC(0-t) in contrast to only 3 of 50 (6."( A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Davidson, MH; Johnson, J; Kling, DF; Kyle, ML; Rooney, MW,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (108)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's37 (34.26)29.6817
2010's71 (65.74)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 69.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index69.94 (24.57)
Research Supply Index5.18 (2.92)
Research Growth Index6.62 (4.65)
Search Engine Demand Index148.00 (26.88)
Search Engine Supply Index2.55 (0.95)

This Compound (69.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials61 (53.04%)5.53%
Reviews13 (11.30%)6.00%
Case Studies3 (2.61%)4.05%
Observational0 (0.00%)0.25%
Other38 (33.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]